E-mail this pagePrint
The Global Pain Pharmaceutical Market Analysis & Forecasts 2007-2022   Publication Date   January 2008 Publisher   VISIONGAIN Product Type   Report Pages   132 ISBN Number   not applicable Product Code   VISG03

The global pain pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 4.56% to 2012.

Visiongain's latest report, "The Global Pain Pharmaceutical Market 2007-2022 ", explains just how this market will experience growth over the medium term future. The report also highlights forecast for 2022, so that you and your company can make longer term plans. Don't let your competitors get the head-start on you, order this report today.

Key questions answered in this report
1. Current and future key products that will drive the pain market
2. The affects of patent expiry on key blockbuster drugs within the pain market
3. How the withdrawal of COX-2 inhibitors impacted the pain market.
4. The key companies involved in the industry, in terms of current and future aims and objectives.
5. How the safety of the narcotic drugs have affected the market
6. The affects of reformulations of existing and new drugs on the market

The world market is currently valued at $31.1bn and revenues are forecasted to increase just under $40bn in 2012. But what will it be in 2022? This report tells you. Do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints in terms of a SWOT analysis. Ensure your organisation is successful in this market by reserving your copy of visiongain's report today.

According to the findings of the new 135+ page report, visiongain reveals that the non-narcotics market is set to dominate the pain market over the forecast period (2007-2012), accounting for almost 36.8% of market revenues by 2012. This market is set for growth right through the next 15 years and this report will help you plan. Reserve your copy today.

Find out who are the major companies involved in the pain market today and in the future. And what R&D opportunities exist for 'new-comers' to the pain pharmaceutical market. Analyse the pipeline of pain products and how it effects your future product launches and partners.

In the process of providing a thorough evaluation of the market, the visiongain pain report focuses on the major market areas including:

1. Anti-Migraine market
2. Anti-Rheumatics non-steroidal market
3. Narcotics market
4. Non-narcotics market

Do you know what the market values of these major therapeutic areas of the pain market are? You should, and this report will tell you.

Plus in-depth analysis of companies, product pipelines and strategies of:

Pfizer

Johnson & Johnson (J&J)

GlaxoSmithKline (GSK)

MundiPharma

Novartis

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC pain drugs by disease and product type. The report also focuses on the technological issues, including the latest trends, patents, new products and other influential factors. The study also assesses the challenges faced by companies in the pain industry, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?
This report features news, insights, the latest developments and an in depth survey of the pain market with up-to-date analysis as well as over 50 tables, graphs and charts. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

Unique benefits to you when you order this report

You can access your report whichever country you are in without using harddrive space

Primary research throughout. You will not find this information anywhere else

Report stored in your reading room for ever

Full searchable report when you buy the company or corporate editions

Copies can be printed off for offline reading

Packed with charts, analysis, figures, graphs and tables

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Additional Information

Organisations mentioned in this report

Abbott
Acrux
Adolor
Alexza
Altea Therapeutics
ALZA
Amgen
Anesiva
Archimedes
Astellas
AstraZeneca
Bayer
Biocon
BioDelivery Sciences International
Biovail
Biovitrum
Boehringer Ingelheim
Bristol-Myers Squibb
Celtic Biotech
CeNeS
Cephalon
Cipher
Cognetix
Columbia Labs
Daiichi Sankyo
Dainippon Sumitomo
DURECT
Eisai
Elan
Elite
Endo
EpiCept
Ethypharm
EVOTEC
Gedeon Richter
Geneva Pharmaceuticals
GlaxoSmithKline
Glenmark
Gruenenthal
Health Canada
Horizon
Houston University
IDEA
Indevus
International Association for the Study of Pain (IASP)
International Narcotics Control Board (INCB)
Intranasal Therapeutics
Javelin
Johnson & Johnson
Kalypsys
King
Labtec
Lead Daiichi Sankyo
Lilly
Limerick NeuroSciences
Lipocine
Manhattan
Medinox
Melbourne University
Merck & Co
MetaPhore
Mundipharma
National Institutes of Health (NIH)
Nektar
NeurogesX
New River Pharmaceuticals
Newron
NicOx
Novartis
Nycomed Pharma
Organon
Ortho-McNeil
Pacira Pharmaceuticals
Pain Therapeutics/King
Palau Pharma
Penwest
Pfizer
PharmaNova
Pharmos
Phosphagenics
Pierre Fabre
Plethora Solutions
PLx Pharma
Pohl Boskamp
POZEN
ProEthic
Purdue
Purdue/Mundipharma
Ranbaxy
Reckitt Benckiser
Renovis
ROXRO
Sanofi-Aventis
SantoSolve
Solvay
Sosei
Stiefel
Synosia
Syntem
Taisho
TheraQuest
Titan
Toko
Toray
TorreyPines
Trophos
UCB
University of Michigan
Vela
Ventech
Vernalis
WEX
Winston Laboratories
World Health Organisation (WHO)
Wyeth
Xenome
YM BioSciences
ZARS

Chapter 1 Executive Summary

Chapter 2 Introduction

2.1 What is Pain?

2.1.1 Historical aspects of Pain

2.2 Pain Pathways

2.2.1 WHO Pain Ladder

2.3 Classification and Types of Pain

2.3.1 Acute Pain

2.3.2 Chronic Pain

2.3.2.1 Psychosocial Effects of Chronic Pain

2.3.2.2 The Financial Burden of Chronic Pain

2.3.2.3 Chronic Cancer Pain

2.3.2.4 Breakthrough Cancer Pain

2.4 Neuropathic Pain

2.4.1 Distinguishing Neuropathic Pain

2.5 Neurochemistry of Pain

2.5.1 Prostaglandins

2.5.2 Opioids

2.6 Pain treatments

2.7 OTC Pain relievers

Chapter 3 The World Pain Pharmaceutical Market

3.1 The World Pain Pharmaceutical Market Analysis

3.1.1 Forces Affecting the Pain Market

3.1.1.1 SWOT Analysis of the Pain Market

3.1.1.2 Market Drivers

3.1.1.3 Market Restraints

3.1.2 The Pain Market Suffered After the Withdrawal of COX-2 Inhibitors

3.1.3 Lack of Adequate Reimbursement Limits Potential of Pain Drugs

3.1.4 Patients Dependent on Reformulations of Existing Drugs

3.1.5 The Narcotics Market Suffers Greatly from Serious Side Effects

3.1.6 The Under-treatment of Pain

3.1.7 How Might These Findings Affect the Market for Pain Management Pharmaceuticals?

3.1.8 The Future of the Pain Market - Closing Comments

3.1.8.1 Shortcomings in the Attitude Towards Pain Management Illustrate the Need for the Proper Use of New and Existing Pain Management Therapies

3.1.8.2 Analgesic Effect of Established Drugs for Other Diseases Will Continue to be of Relevance to the Pain Management Market

3.1.8.3 Personalized Pain Management Therapy

Chapter 4 The Anti-Migraine Market

4.1 Headache Pain

4.1.1 Tension Headaches

4.1.2 Migraine Headaches

4.2 Prevalence of Migraine

4.2.1 Why Will the Prevalence of Migraine Increase?

4.3 Medications for the Prevention and Treatment of Migraine Pain

4.3.1 Acute Symptomatic relief of migraine pain

4.3.2 Selective Serotonin Agonists (Triptans)

4.3.2.1 Sumatriptan (Imitrex)

4.3.2.2 Rizatriptan (Maxalt)

4.3.2.3 Zolmitriptan (Zomig)

4.3.2.4 Eletriptan (Relpax)

4.3.2.5 Naratriptan (Naramig)

4.3.3 Ergots Used in the Treatment of Migraine Pain

4.3.4 Prophylatic Medicines

4.4 Top Five Products in the Market and Revenues, 2006

4.5 Market Analysis

4.5.1 GSK's Blockbuster Migraine Drug Imitrex Faces Loss of Sales

4.5.1.1 GSK Waiting Approval for New Potential Anti-Migraine Blockbuster Drug

4.5.2 AstraZeneca's Zomig - The New Market Leader Perhaps?

4.5.3 Relpax Shows Positive Revenue

4.5.4 What Does the Future Hold for Migraine Therapy?

4.5.5 What are the Unmet Needs in the Management of Migraine?

4.5.6 Why the Market will Grow

4.6 Pipeline Drugs for Treating Migraines

Chapter 5 Anti-Rheumatic Non-Steroidal Market

5.1 What is Arthritis?

5.1.1 Osteoarthritis

5.1.2 Rheumatoid Arthritis (RA)

5.1.2.1 Causes and Features of RA

5.1.2.2 Symptoms of RA

5.1.2.3 Diagnosing RA

5.2 Prevalence in the Seven Major Pharmaceutical Markets

5.2.1 Why will the Prevalence of Arthritis Increase

5.3 Forms of Drug Treatment

5.3.1 NSAIDs

5.3.2 COX-2

5.3.2.1 Side Effects

5.3.3 Analgesics

5.4 An Overview of the Top Five Drugs in the Anti-Rheumatic Non-Steroidal Market, 2006

5.4.1 Celebrex (Celecoxib, Pfizer)

5.4.2 Mobic (Meloxicam, Boehringer Ingelheim)

5.4.3 Voltaren (Diclofenac, Novartis)

5.4.4 Arthrotec (Diclofenac/Misoprostol, Pfizer)

5.4.5 Arcoxia (Etoricoxib, Merck & Co)

5.5 The Global Anti-Rheumatic Market Analysis

5.5.1 Pfizer's Celebrex Dominates the Market, but will it last?

5.5.2 Mobic Suffers from Generic Competition

5.5.3 Arcoxia Has Reduced Gastro Intestinal Effects

5.5.4 Rises Predicted for Global Arthritis Market

5.5.5 NSAIDs - Coxibs (SWOT analysis)

5.6 Anti-Rheumatic Non-Steroidal Drugs in the Pipeline for Pain, 2007

Chapter 6 The Narcotics Market

6.1 Introduction to Opioids

6.1.1 Opioids Cellular Mechanism of Action

6.1.1.1 Peripheral and central opioid receptors

6.1.1.2 Peripheral opioid receptors and tissue injury

6.1.1.3 Tolerance at peripheral opioid receptors

6.1.1.4 Endogenous ligands of peripheral opioid receptors

6.1.1.5 Migration of opioid-producing cells to injured tissue

6.1.1.6 Opioid secretion and peripheral pain control

6.1.2 Analgesia

6.1.3 Euphoria

6.1.4 Respiratory depression

6.1.5 Effects on gastrointestinal tract

6.1.6 Tolerance and dependence

6.1.6.1 Tolerance

6.1.6.2 Physical dependence

6.1.7 Preclinical studies on peripheral opioid analgesics

6.1.7.1 Clinical studies on peripheral opioid analgesics

6.1.7.2 Perspectives

6.2 Regulatory limitations on the use and distribution of narcotic drugs

6.2.1 The International Narcotics Control Board

6.2.2 The WHO and the prevention of drug abuse

6.2.3 National drug policies and the control of medical agents with

the potential for abuse

6.2.4 Does the control of substances with the potential for abuse limit their availability for legitimate use?

6.3 Commonly Used Opioid Analgesics

6.3.1 Morphine

6.3.2 Fentanyl

6.3.3 Oxycodone

6.3.4 Methadone

6.4 Top Products in the Narcotics Market

6.4.1 Oxycontin (Oxycodone, Purdue Pharma)

6.4.2 Duragesic (Fentanyl, J&J)

6.4.3 Actiq (Fentanyl, Cephalon)

6.5 The World Narcotics Market Analysis

6.5.1 Oxycontin - Associated with Abuse and Addiction

6.5.2 Duragesic - Defective Patches

6.5.3 Actiq Suffers Greatly from Generic Competition

6.6 Narcotic Drugs in the Pipeline for Pain

Chapter 7 Non-Narcotics Market

7.1 Non-Opioids

7.2 Non-steroidal anti-inflammatory drugs (NSAIDS)

7.2.1 Pharmacological actions

7.2.1.1 The prostaglandin pathway

7.3 The salicyclates and paracetamol

7.3.1 The salicylates

7.3.2 Pharmacokinetics

7.3.3 Common unwanted effects

7.3.4 Gastrointestinal disturbances

7.4 Top Four Products in the Non-Narcotics Market

7.4.1 Advil (Ibuprofen, Wyeth)

7.4.2 Tylenol (Paracetamol, J&J)

7.4.3 Aspirin Bayer (Acetylsalicylic Acid, Bayer)

7.4.4 Efferalgan (Paracetamol, Bristol-Myers Squibb)

7.5 The World Non-Narcotics Market Analysis

7.5.1 Tylenol Set to Reach Blockbuster Status

7.5.2 Aspirin Bayer - Huge Amount of Line Extensions Keeping Sales Up

7.5.3 Advil Set to Become Top Product in the Non-Narcotics Market

7.6 Non-Narcotics Drugs in the Pipeline for Pain

Chapter 8 Future Therapies

8.1 Cannabinoids and Pain: An Alternative to Opioids?

8.1.1 Experimentally Induced Acute Pain

8.1.2 Post Surgical Acute Pain

8.1.3 Chronic Pain

8.1.4 Sativex

8.1.4.1 European Phase III trials of Sativex

8.1.4.2 Sativex Approved for Cancer Pain

8.1.5 Cannabinoids and Pain: A Lucrative Market?

8.2 The Future of Pain Research

8.3 Advanced drug delivery

8.3.1 Delivery of poorly soluble drugs

8.3.2 Examples of Poorly Water Soluble Drugs

Chapter 9 Top Companies

9.1 Pfizer

9.2 Johnson & Johnson (J&J)

9.3 GlaxoSmithKline (GSK)

9.4 MundiPharma

9.5 Novartis

Chapter 10 Conclusion

10.1 The Pain Market is Headed for High Consistent Financial Growth

List of tables

Table 3.1 The Worldwide Pain Pharmaceutical Market Forecast ($m), 2007-2022

Table 3.2 Worldwide Pharmaceutical Pain Market Forecast by Area ($m), 2007-2022

Table 3.3 Top ten products in the pain market ($m), 2007

Table 3.4 A SWOT Chart for the Pain Market, 2007-2012

Table 4.1 Top five drugs in the anti-migraine market and 2006 sales

Table 4.2 The World Anti-Migraine Product Forecast ($m), 2007-2022

Table 4.3 Imitrex Forecast ($m), 2007-2012

Table 4.4 Zomig Forecast ($m), 2007-2012

Table 4.5 Relpax Forecast ($m), 2007-2012

Table 4.6 Anti-Migraine Pipeline Drugs for Pain, 2007

Table 5.1 Top Five Drugs in the Anti-Rheumatic Non-Steroidal Market and Revenue, 2006

Table 5.2 The Global Anti-Rheumatic Non-Steroidal Market Forecast ($m), 2007-2022

Table 5.3 Celebrex Forecast ($m), 2007-2012

Table 5.4 Mobic Forecast ($m), 2007-2012

Table 5.5 Arcoxia Forecast ($m), 2007-2012

Table 5.6 SWOT Analysis of the COX- Inhibitors

Table 5.7 Anti-Rheumatic Non-Steroidal Pipeline Drugs for Pain, 2007

Table 6.1 Top Four Products in the Narcotics Market and Revenue, 2006

Table 6.2 The World Narcotics Product Market Forecast ($m), 2007-2022

Table 6.3 Oxycontin Revenue Forecast ($m), 2007-2012

Table 6.4 Duragesic Revenue Forecast ($m), 2007-2012

Table 6.5 Actiq Revenue Forecast ($m), 2007-2012

Table 6.6 Narcotic Drugs in the Pipeline for Pain, 2007

Table 7.1 Top Four Products in the Non-Narcotics Market and Revenue, 2006

Table 7.2 The Total World Non-Narcotics Products Market Forecast ($m), 2007-2022

Table 7.3 Tylenol Market Forecast ($m), 2007-2012

Table 7.4 Aspirin Bayer Market Forecast ($m), 2007-2012

Table 7.5 Advil Market Forecast ($m), 2007-2012

Table 7.6 Non-Narcotics Drugs in the Pipeline for Pain, 2007

Table 9.1 Top five companies in the pain market ($bn), 2006

List of graphs

Graph 3.1 The World Pain Pharmaceutical Market Revenue Forecast ($m), 2007-2012

Graph 3.2 Pain Area Market Share (%), 2006, 2009 and 2012

Graph 4.1 Anti-Migraine World Market Forecast ($m), 2007-2012

Graph 4.2 Imitrex Revenue Forecast ($m), 2007-2012

Graph 4.3 Zomig Revenue Forecast ($m), 2007-2012

Graph 4.4 Relpax Revenue Forecast ($m), 2007-2012

Graph 5.1 The Anti-Rheumatic Non-Steroidal Market Revenue Forecast ($m), 2007-2012

Graph 5.2 Celebrex Revenue Forecast ($m), 2007-2012

Graph 5.3 Mobic Revenue Forecast ($m), 2007-2012

Graph 5.4 Arcoxia Revenue Forecast ($m), 2007-2012

Graph 6.1 The World Narcotics Revenue Forecast ($m), 2007-2012

Graph 6.2 Oxycontin Revenue Forecast ($m), 2007-2012

Graph 6.3 Duragesic Revenue Forecast ($m), 2007-2012

Graph 6.4 Actiq Revenue Forecast ($m), 2007-2012

Graph 7.1 The World Non-Narcotics Market Revenue Forecast ($m), 2007-2012

Graph 7.2 Tylenol Revenue Forecast ($m), 2007-2012

Graph 7.3 Aspirin Bayer Revenue Forecast ($m), 2007-2012

Graph 7.4 Advil Revenue Forecast ($m), 2007-2012

Graph 9.1 Pfizer's total sales ($m), 2001-2005

Graph 9.2 Pfizer's R&D expenditure ($m), 2001-2005

Graph 9.3 J&J's Company Results ($bn), 2006

Graph 9.4 GSK's Company Results ($bn), 2006

Graph 9.5 Novartis' total sales ($m), 2001-2005

Graph 9.6 Novartis R&D expenditure ($m), 2001-2005

List of charts

Chart 3.1 Pain Area Market Share (%), 2006

Chart 3.2 Pain Area Market Share (%), 2009

Chart 3.3 Pain Area Market Share (%), 2012

Chart 3.3 Pain Area Market Share (%), 2017

Chart 3.3 Pain Area Market Share (%), 2022